Announcement on Approval of Marketing Application for Amlodipine Besylate Chemical API

Rundu Co., Ltd.·July 21, 2026·2 pages

✨ AI Summary

Zhuhai Rundu Pharmaceutical Co., Ltd. announces it has received approval from China's NMPA for its Amlodipine Besylate chemical API. This approval enhances the company's cardiovascular product portfolio and vertical integration strategy. The company anticipates market sales may be affected by policy and market changes.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002923

Stock Abbreviation: Rundu Pharmaceutical

Announcement No.: 2026-052

Zhuhai Rundu Pharmaceutical Co., Ltd.

Announcement on Approval of Marketing Application for Amlodipine Besylate Chemical API

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or significant omissions.

Zhuhai Rundu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently received the "Chemical API Marketing Application Approval Notice" for Amlodipine Besylate (hereinafter referred to as "this product") issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Basic Information of the Drug

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.